During the last session, Xeris Pharmaceuticals Inc. (NASDAQ:XERS)’s traded shares were 2.54 million. At the end of the trading day, the stock’s price was $3.96, reflecting an intraday loss of -1.25% or -$0.05. The 52-week high for the XERS share is $7.94, that puts it down -100.51 from that peak though still a striking 38.13% gain since the share price plummeted to a 52-week low of $2.45. The company’s market capitalization is $249.84M, and the average intraday trading volume over the past 10 days was 7.97 million shares, and the average trade volume was 3.00 million shares over the past three months.
Xeris Pharmaceuticals Inc. (XERS) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. XERS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.31.
Xeris Pharmaceuticals Inc. (NASDAQ:XERS) trade information
Xeris Pharmaceuticals Inc. (XERS) registered a -1.25% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.25% in intraday trading to $3.96 this Thursday, 06/10/21, hitting a weekly high. The stock’s 5-day price performance is 2.86%, and it has moved by 15.79% in 30 days. Based on these gigs, the overall price performance for the year is -21.27%. The short interest in Xeris Pharmaceuticals Inc. (NASDAQ:XERS) is 15.29 million shares and it means that shorts have 6.68 day(s) to cover.
The consensus price target of analysts on Wall Street is $9.67, which implies an increase of 59.05% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $11.00 respectively. As a result, XERS is trading at a discount of -177.78% off the target high and -127.27% off the low.
Xeris Pharmaceuticals Inc. (XERS) estimates and forecasts
Statistics show that Xeris Pharmaceuticals Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Xeris Pharmaceuticals Inc. (XERS) shares have gone down -3.41% during the last six months, with a year-to-date growth rate more than the industry average at 47.20% against 16.70. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 50.80% this quarter and then jump 20.00% in the quarter after that. In the rating firms’ projections, revenue will increase 132.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $9.17 million as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $13.4 million by the end of Sep 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.86 million and $9.4 million respectively. In this case, analysts expect current quarter sales to grow by 393.00% and then jump by 42.50% in the coming quarter.
While earnings are projected to return 55.60% in 2021.
Xeris Pharmaceuticals Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Xeris Pharmaceuticals Inc. (NASDAQ:XERS)’s Major holders
Xeris Pharmaceuticals Inc. insiders own 0.98% of total outstanding shares while institutional holders control 51.91%, with the float percentage being 52.43%. Deerfield Management Company, L.P. (Series C) is the largest shareholder of the company, while 141 institutions own stock in it. As of Mar 30, 2021, the company held over 6.55 million shares (or 9.88% of all shares), a total value of $29.56 million in shares.
The next largest institutional holding, with 3.76 million shares, is of Blackrock Inc.’s that is approximately 5.67% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $16.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of Xeris Pharmaceuticals Inc. (XERS) shares are Invesco Global Opportunities Fund and Vanguard Total Stock Market Index Fund. Data provided on Jan 30, 2021 indicates that Invesco Global Opportunities Fund owns about 2.0 million shares. This amounts to just over 3.01 percent of the company’s overall shares, with a $10.16 million market value. The same data shows that the other fund manager holds slightly less at 1.58 million, or about 2.39% of the stock, which is worth about $7.15 million.